Abstract
The most rigorous and accurate approach to evaluating clinical events in cancer screening studies is to use data obtained through medical record abstraction (MRA). Although MRA is complex, the particulars of the procedure—such as the specific training and quality assurance processes, challenges of implementation, and other factors that influence the quality of abstraction—are usually not described in reports of studies that employed the technique. In this paper, we present the details of MRA activities used in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which used MRA to determine primary and secondary outcomes and collect data on other clinical events. We describe triggers of the MRA cycle and the specific tasks that were part of the abstraction process. We also discuss training and certification of abstracting staff, and technical methods and communication procedures used for data quality assurance. We include discussion of challenges faced and lessons learned.
Keywords: Abstraction, medical record abstraction, medical record requests, quality assurance, screening.
Reviews on Recent Clinical Trials
Title:Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial
Volume: 10 Issue: 3
Author(s): Bazzi Latifa, Lamerato Lois E, Varner Julie, Shambaugh Vicki L., Cordes Jill E, Ragard Lawrence R and Marcus Pamela M
Affiliation:
Keywords: Abstraction, medical record abstraction, medical record requests, quality assurance, screening.
Abstract: The most rigorous and accurate approach to evaluating clinical events in cancer screening studies is to use data obtained through medical record abstraction (MRA). Although MRA is complex, the particulars of the procedure—such as the specific training and quality assurance processes, challenges of implementation, and other factors that influence the quality of abstraction—are usually not described in reports of studies that employed the technique. In this paper, we present the details of MRA activities used in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, which used MRA to determine primary and secondary outcomes and collect data on other clinical events. We describe triggers of the MRA cycle and the specific tasks that were part of the abstraction process. We also discuss training and certification of abstracting staff, and technical methods and communication procedures used for data quality assurance. We include discussion of challenges faced and lessons learned.
Export Options
About this article
Cite this article as:
Latifa Bazzi, Lois E Lamerato, Julie Varner, Vicki L. Shambaugh, Jill E Cordes, Lawrence R Ragard and Pamela M Marcus, Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial, Reviews on Recent Clinical Trials 2015; 10 (3) . https://dx.doi.org/10.2174/1574887110666150731145421
DOI https://dx.doi.org/10.2174/1574887110666150731145421 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of the Shortest Path Algorithm for the Discovery of Breast Cancer-Related Genes
Current Bioinformatics Guanine Content of MicroRNAs is Associated with their Tumor- Suppressive and Oncogenic Roles in Lung and Breast Cancers
MicroRNA Feasibility of a Scale-down Production of [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4 in a Hospital Based Radiopharmacy
Current Radiopharmaceuticals Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates
Current Cancer Drug Targets Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Overview on Anticancer Drug Design and Development
Current Medicinal Chemistry Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Current Medicinal Chemistry The Renaissance of the 68Ge/68Ga Radionuclide Generator Initiates New Developments in 68Ga Radiopharmaceutical Chemistry
Current Topics in Medicinal Chemistry Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry The Medical and Medico-legal Complications of Bulimia Nervosa : Treatments and Complications
Current Women`s Health Reviews Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Diffuse Correlation Spectroscopy (DCS): A Diagnostic Tool for Assessing Tissue Blood Flow in Vascular-Related Diseases and Therapies
Current Medical Imaging Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Medicinal Chemistry Approaches of Controlling Gastrointestinal Side Effects of Non-Steroidal Anti-Inflammatory Drugs. Endogenous Protective Mechanisms and Drug Design
Medicinal Chemistry Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets The IGF-I/IGF-I Receptor Pathway: Implications in the Pathophysiology of Thyroid Cancer
Current Medicinal Chemistry Development and Characterization of Triple Action-Dental Mold
Current Dentistry